Stock listing
Frankfurt:LT4 Liquidia Corporation Aktie
German listing (Frankfurt) of Liquidia Corporation · home listing NASDAQ:LQDA
Follow Liquidia Corporation into a list and get an email when it puts out news.
Share price · FWB:LT4
€51.08 EUR -0.30 (-0.6%)
Close on Nov 20, 2026
- Day range
- €51.08 – €51.08 EURNov 20, 2026
- Market cap
- €4.57B EURAt the close on Nov 20, 2026 · price × 89.51M shares outstanding
- 52-week range
- €21.99 – €79.70 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €32,910 EURMedian day 69 shares · 22 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:LQDA · Home | $54.43 USD | -1.97 (-3.5%) | 1,690,880 | $56.49 | $57.21 | $53.98 | $56.40 | Close on Nov 20, 2026 |
| Frankfurt:LT4 | €51.08 EUR | -0.30 (-0.6%) | — | €51.08 | €51.08 | €51.08 | €51.38 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:LT4 · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €39.46 | -2.196 | -5.3% | €39.46 | €39.46 | €39.46 | 0 | |
| €41.65 | +4.582 | +12.4% | €41.65 | €41.65 | €41.65 | 456 | |
| €37.07 | +0.172 | +0.5% | €37.07 | €37.07 | €37.07 | 456 | |
| €36.90 | -3.225 | -8.0% | €37.00 | €37.01 | €36.84 | 0 | |
| €40.13 | +1.002 | +2.6% | €40.13 | €40.13 | €40.13 | 0 | |
| €39.12 | -1.418 | -3.5% | €39.12 | €39.12 | €39.12 | 704 | |
| €40.54 | +0.408 | +1.0% | €40.54 | €40.54 | €40.54 | 10 | |
| €40.13 | +1.055 | +2.7% | €40.13 | €40.13 | €40.13 | 15 | |
| €39.08 | -0.504 | -1.3% | €39.08 | €39.08 | €39.08 | 1,040 | |
| €39.58 | +4.757 | +13.7% | €38.00 | €40.67 | €37.91 | 1,040 | |
| €34.83 | +1.188 | +3.5% | €34.83 | €34.83 | €34.83 | 28 | |
| €33.64 | +1.789 | +5.6% | €33.64 | €33.64 | €33.64 | 500 | |
| €31.85 | +1.845 | +6.1% | €31.85 | €31.85 | €31.85 | 0 | |
| €30.00 | -0.771 | -2.5% | €30.00 | €30.00 | €30.00 | 0 | |
| €30.77 | +0.196 | +0.6% | €30.77 | €30.77 | €30.77 | 0 | |
| €30.58 | +1.003 | +3.4% | €30.95 | €30.95 | €30.49 | 0 | |
| €29.58 | -4.923 | -14.3% | €29.58 | €29.58 | €29.58 | 0 | |
| €34.50 | +10.57 | +44.2% | €34.59 | €34.71 | €34.48 | 365 | |
| €23.93 | -2.001 | -7.7% | €24.51 | €24.62 | €23.91 | 120 | |
| €25.93 | +1.34 | +5.5% | €24.80 | €25.97 | €24.77 | 218 | |
| €24.59 | +0.841 | +3.5% | €24.59 | €24.59 | €24.59 | 290 | |
| €23.75 | +1.019 | +4.5% | €23.75 | €23.75 | €23.75 | 34 | |
| €22.73 | -1.633 | -6.7% | €22.73 | €22.73 | €22.73 | 1,200 | |
| €24.36 | -0.842 | -3.3% | €24.35 | €24.51 | €24.26 | 100 | |
| €25.20 | +0.353 | +1.4% | €25.20 | €25.20 | €25.20 | 0 | |
| €24.85 | +1.924 | +8.4% | €24.85 | €24.85 | €24.85 | 27,158 | |
| €22.92 | -12.03 | -34.4% | €27.07 | €27.34 | €21.99 | 4,413 | |
| €34.96 | -29.50 | -45.8% | €62.16 | €62.40 | €31.79 | 3,811 | |
| €64.46 | +4.747 | +8.0% | €64.46 | €64.46 | €64.46 | 200 | |
| €59.71 | -2.216 | -3.6% | €59.71 | €59.71 | €59.71 | 20 | |
| €61.92 | +2.933 | +5.0% | €61.92 | €61.92 | €61.92 | 266 | |
| €58.99 | -0.335 | -0.6% | €58.99 | €58.99 | €58.99 | 0 | |
| €59.33 | +1.493 | +2.6% | €59.33 | €59.33 | €59.33 | 0 | |
| €57.83 | 0.00 | 0.0% | €57.83 | €57.83 | €57.83 | 0 | |
| €57.83 | -1.386 | -2.3% | €57.93 | €57.93 | €57.68 | 69 | |
| €59.22 | -0.071 | -0.1% | €59.22 | €59.22 | €59.22 | 5,306 | |
| €59.29 | +2.943 | +5.2% | €59.29 | €59.29 | €59.29 | 0 | |
| €56.35 | -0.024 | 0.0% | €56.35 | €56.35 | €56.35 | 0 | |
| €56.37 | -0.754 | -1.3% | €56.37 | €56.37 | €56.37 | 0 | |
| €57.13 | -1.737 | -3.0% | €57.17 | €57.17 | €57.09 | 500 | |
| €58.86 | +0.382 | +0.7% | €57.94 | €58.93 | €57.90 | 152 | |
| €58.48 | -0.498 | -0.8% | €58.48 | €58.48 | €58.48 | 0 | |
| €58.98 | +0.56 | +1.0% | €58.21 | €59.38 | €58.07 | 175 | |
| €58.42 | -0.088 | -0.2% | €58.42 | €58.42 | €58.42 | 0 | |
| €58.51 | -0.237 | -0.4% | €58.51 | €58.51 | €58.51 | 0 | |
| €58.74 | -1.152 | -1.9% | €58.74 | €58.74 | €58.74 | 810 | |
| €59.90 | +2.366 | +4.1% | €59.90 | €59.90 | €59.90 | 16 | |
| €57.53 | -0.997 | -1.7% | €57.42 | €57.88 | €57.37 | 286 | |
| €58.53 | +0.777 | +1.3% | €58.53 | €58.53 | €58.53 | 127 | |
| €57.75 | -1.566 | -2.6% | €57.75 | €57.75 | €57.75 | 315 | |
| €59.32 | -1.74 | -2.8% | €59.39 | €59.39 | €58.41 | 810 | |
| €61.06 | +1.178 | +2.0% | €61.06 | €61.06 | €61.06 | 0 | |
| €59.88 | -0.244 | -0.4% | €59.88 | €59.88 | €59.88 | 0 | |
| €60.12 | +1.576 | +2.7% | €60.12 | €60.12 | €60.12 | 0 | |
| €58.55 | -1.828 | -3.0% | €58.55 | €58.55 | €58.55 | 0 | |
| €60.37 | -3.648 | -5.7% | €60.37 | €60.37 | €60.37 | 2,366 | |
| €64.02 | +0.379 | +0.6% | €64.13 | €64.46 | €63.58 | 1,027 |
- Ticker
- Frankfurt:LT4
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 10, 2026
Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference
Latest earnings call · Nov 10, 2026
Liquidia (NASDAQ:LQDA) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 10, 2026
Q3 2026 Earnings Presentation
Earnings · 10 slides
Latest news
Liquidia Corporation to Report Third Quarter 2026 Financial Results on November 10, 2026
Nov 3, 2026
Closed €36.90 (-8.0%) on Nov 3, 2026
Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH
Oct 13, 2026
Closed €34.50 (+44.2%) on Oct 14, 2026
Liquidia Provides Update on Hatch-Waxman Litigation Tied to ‘327 Patent
Sep 30, 2026
Closed €22.92 (-34.4%) on Oct 1, 2026
FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis
Sep 3, 2026
Closed €59.90 (+4.1%) on Sep 3, 2026
Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress
Sep 2, 2026
Closed €57.53 (-1.7%) on Sep 2, 2026
Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference
Sep 1, 2026
Closed €58.53 (+1.3%) on Sep 1, 2026
Liquidia Corporation Reports Second Quarter 2026 Financial Results
Aug 12, 2026
Closed €68.95 (-12.0%) on Aug 12, 2026
Liquidia Corporation to Report Second Quarter 2026 Financial Results on August 12, 2026
Jul 29, 2026
Closed €75.90 (+2.8%) on Jul 29, 2026
Liquidia Corporation on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 21 in the last 12 months · 196 in all · newest Nov 10, 2026 · oldest 2019
- Calls
- 23 calls with a replay · 23 with a transcript · latest Nov 10, 2026
- Decks
- 10 decks · latest Nov 10, 2026
Where Liquidia Corporation is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:LQDA · Home listing | NASDAQ | United States | USD |
| gettex:LT4 | gettex | Germany | EUR |
| Tradegate:LT4 | Tradegate | Germany | EUR |
| LS Exchange:A2JRNS | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2JRNS | Lang & Schwarz | Germany | EUR |
| BOATS:LQDA | BOATS | United States | USD |
| Frankfurt:LT4 · This page | Frankfurt | Germany | EUR |
| Stuttgart:LT4 | Stuttgart | Germany | EUR |
| Dusseldorf:LT4 | Dusseldorf | Germany | EUR |
| Munich:LT4 | Munich | Germany | EUR |
| Hamburg:LT4 | Hamburg | Germany | EUR |
| Hanover:LT4 | Hanover | Germany | EUR |
| Xetra:LT4 | Xetra | Germany | EUR |
Valuation
EV/sales 7.5× against a median of 5.7×: 6th lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $4.68B USD
- P/E
- Loss
- EV/sales
- 7.5×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- 92.7%
- Operating margin
- −15.6%
- Net margin
- −15.2%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 0.84
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Liquidia Corporation · NASDAQ:LQDA | US$4.90B | US$4.68B | n/a | 7.5× | n/a | n/a | −15.2% | n/a | 0.84 |
| Belite Bio, Inc. · NASDAQ:BLTE | US$5.13B | US$5.13B | n/a | n/a | n/a | 6.6× | n/a | 0.0× | 1.34 |
| SK Biopharmaceuticals Co., Ltd. · KRX:326030 | US$5.05B | US$4.77B | 16.9× | 7.5× | 20.1× | 6.7× | 46.6% | 0.0× | n/a |
| Veradermics, Incorporated · NYSE:MANE | US$5.04B | US$4.25B | n/a | n/a | n/a | 6.3× | n/a | 0.0× | 1.13 |
| Erasca, Inc. · NASDAQ:ERAS | US$4.78B | US$4.18B | n/a | n/a | n/a | 5.2× | n/a | 0.1× | 1.51 |
| Dianthus Therapeutics, Inc. · NASDAQ:DNTH | US$4.76B | US$3.92B | n/a | 1,444× | n/a | 3.8× | n/a | 0.0× | 0.90 |
| PTC Therapeutics, Inc. · NASDAQ:PTCT | US$4.71B | US$3.12B | n/a | 2.7× | n/a | n/a | −9.2% | n/a | 0.88 |
| Cogent Biosciences, Inc. · NASDAQ:COGT | US$4.65B | US$4.08B | n/a | n/a | n/a | 9.0× | n/a | 0.4× | 1.30 |
| Kiniksa Pharmaceuticals International, plc · NASDAQ:KNSA | US$4.53B | US$3.97B | 41.4× | 4.2× | 29.9× | 6.4× | 11.6% | 0.0× | 0.57 |
| Travere Therapeutics, Inc. · NASDAQ:TVTX | US$4.51B | US$4.21B | n/a | 6.5× | n/a | 200× | −18.7% | 0.0× | 1.31 |
| Ionis Pharmaceuticals, Inc. · NASDAQ:IONS | US$4.43B | US$4.70B | n/a | 4.9× | n/a | 11.3× | −56.9% | 5.5× | 0.40 |
| Median of the others | US$4.74B | US$4.19B | 29.2× | 5.7× | 25.0× | 6.6× | −9.2% | 0.0× | 1.13 |
Forecasts
5 strong buy · 1 buy · 2 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 66.13 USD · Analysts' mean
- EPS, year to Dec 2026
- 0.075 · 2 analysts
- Revenue, year to Dec 2026
- 759.6M · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Roger Jeffs | Chief Executive Officer |
| Patrick Wallace | Director, Corporate Communications |
| Jason Adair | Chief Business Officer |
Board
| Director | Role |
|---|---|
| Stephen Bloch | Chairman |
| Arthur Kirsch | Board Member |
| Damian deGoa | Board Member |
| David Johnson | Board Member |
| Joanna Horobin | Board Member |
| Katie Rielly-Gauvin | Board Member |
| Paul Manning | Board Member |
| Raman Singh | Board Member |
| Roger Jeffs | Chief Executive Officer |
Events
Calls
| Call | When | Status |
|---|---|---|
| Liquidia (NASDAQ:LQDA) Q3 2026 Earnings Call | Tue, Nov 10, 2026 · 8:30 AM ET | Replay |
| Liquidia (NASDAQ:LQDA) Q2 2026 Earnings Call | Wed, Aug 12, 2026 · 8:30 AM ET | Replay |
| Liquidia (NASDAQ:LQDA) Q1 2026 Earnings Call | Mon, May 11, 2026 · 8:30 AM ET | Replay |
| Liquidia (NASDAQ:LQDA) Q4 2025 Earnings Call | Thu, Mar 05, 2026 · 8:30 AM ET | Replay |
| Liquidia (NASDAQ:LQDA) Q3 2025 Earnings Call | Mon, Nov 03, 2025 · 8:30 AM ET | Replay |
| Liquidia (NASDAQ:LQDA) Q2 2025 Earnings Call | Tue, Aug 12, 2025 · 8:30 AM ET | Replay |
| Liquidia (NASDAQ:LQDA) Q1 2025 Earnings Call | Thu, May 08, 2025 · 8:30 AM ET | Replay |
| Liquidia (NASDAQ:LQDA) Q4 2024 Earnings Call | Wed, Mar 19, 2025 · 8:30 AM ET | Replay |
| Liquidia (NASDAQ:LQDA) Q3 2024 Earnings Call | Wed, Nov 13, 2024 · 8:30 AM ET | Replay |
| Liquidia (NASDAQ:LQDA) Q2 2024 Earnings Call | Wed, Aug 07, 2024 · 8:30 AM ET | Replay |
All 23 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · Before open | +7.4% |
| Q2 2026 | Aug 12, 2026 · Before open | −10.5% |
| Q1 2026 | May 11, 2026 · Before open | +25.6% |
| Q4 2025 | Mar 12, 2026 | −4.9% |
| Q3 2025 | Nov 3, 2025 · Before open | +3.5% |
| Q2 2025 | Aug 12, 2025 · Before open | +13.7% |
| Q1 2025 | May 8, 2025 · Before open | −1.2% |
| Q4 2024 | Mar 19, 2025 | +4.8% |
| Q3 2024 | Nov 13, 2024 · Before open | −3.4% |
| Q2 2024 | Aug 7, 2024 · Before open | −3.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 13, 2024 · After close | −1.5% |
| Q4 2023 | Mar 13, 2024 · Before open | +5.4% |
| Q3 2023 | Nov 7, 2023 · Before open | +3.7% |
| Q2 2023 | Aug 10, 2023 · Before open | +3.1% |
| Q1 2023 | May 4, 2023 · After close | +1.1% |
| Q4 2022 | Mar 16, 2023 · Before open | +15.3% |
| Q3 2022 | Nov 8, 2022 · After close | +0.4% |
| Q2 2022 | Aug 11, 2022 · After close | +27.9% |
| Q1 2022 | May 12, 2022 · After close | +13.9% |
| Q4 2021 | Mar 17, 2022 · Before open | +5.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 10 slides | Nov 10, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 12 slides | Aug 12, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 10 slides | May 11, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 8 slides | Mar 5, 2026 |
| J.P. Morgan Healthcare Conference 2026 | Conference | 21 slides | Jan 14, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 9 slides | Nov 3, 2025 |
| Investor Day (October 2025) | Investor day | 62 slides | Oct 28, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 9 slides | Aug 12, 2025 |
| Corporate Update (May 2025) | Corporate update | 12 slides | May 27, 2025 |
| J.P. Morgan Healthcare Conference 2025 | Conference | 22 slides | Jan 15, 2025 |
Financings
| Raise | Date |
|---|---|
| Royalty financing (sixth amendment to HCRx agreement) Tranche closed: US$50M raised Buyers: HealthCare Royalty (HCRx) (funded an additional $50.0 million) Use of proceeds: Accelerate YUTREPIA launch, advance clinical pipeline, and expand manufacturing including build-out of newly leased facility | Jun 23, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 158.3M | 14.0M | 17.5M | 15.9M | 12.9M | 739.6K | 8.07M | 2.71M | 7.26M | 13.2M |
| Cost of revenue | 13.2M | 5.88M | 2.89M | 2.86M | 3.02M | 237.7K | 807.2K | 121.4K | 319.8K | 918.8K |
| Gross profit | 145.1M | 8.12M | 14.6M | 13.1M | 9.83M | 501.9K | 7.26M | 2.59M | 6.94M | 12.3M |
| Research and development | 39.3M | 47.8M | 43.2M | 19.4M | 20.5M | 32.2M | 40.5M | 28.7M | 24.8M | 23.3M |
| Selling, general and administrative | 157.2M | 81.6M | 44.7M | 32.4M | 23.1M | 27.4M | 13.6M | 8.75M | 10.2M | 4.84M |
| Operating income | -51.4M | -121.3M | -73.4M | -38.8M | -33.8M | -59.1M | -46.8M | -34.9M | -28.0M | -15.9M |
| Depreciation and amortization | 1.53M | 2.20M | 2.18M | 3.65M | 5.61M | 3.13M | 2.57M | 1.54M | 931.9K | 651.6K |
| EBITDA | -49.8M | -119.1M | -71.2M | -35.1M | -28.2M | -56.0M | -44.3M | -33.3M | -27.1M | -15.2M |
| Interest expense | 24.2M | 14.7M | 6.27M | 2.34M | 762.0K | 858.0K | 1.37M | 19.0M | 13.0M | 85.9K |
| Income before tax | -68.9M | -130.4M | -78.5M | -41.0M | -34.6M | -59.8M | -47.6M | -53.1M | -29.2M | -15.9M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 720.4K | 13.0M | 14.9K |
| Net income | -68.9M | -128.3M | -78.5M | -41.0M | -34.6M | -59.8M | -47.6M | -53.1M | -29.2M | -15.9M |
| Earnings per share, basic | -0.80 | -1.63 | -1.21 | -0.67 | -0.70 | -1.76 | -2.57 | -7.42 | -3.40 | -3.13 |
| Earnings per share, diluted | -0.80 | -1.63 | -1.21 | -0.67 | -0.70 | -1.76 | -2.57 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 190.7M | 176.5M | 83.7M | 93.3M | 57.5M | 65.3M | 55.8M | 39.5M | 3.42M | 1.44M |
| Receivables | 54.1M | 2.72M | 4.06M | 5.02M | 2.99M | 0 | 272.6K | 1.62M | 1.24M | |
| Inventory | 23.8M | 241.0K | 1 | 1 | 1 | 1 | ||||
| Current assets | 273.4M | 185.1M | 89.9M | 99.8M | 61.3M | 66.1M | 56.4M | 40.0M | 5.48M | 3.15M |
| Property, plant and equipment | 11.8M | 8.30M | 4.48M | 4.15M | 5.02M | 6.81M | 9.25M | 8.13M | 8.24M | 4.35M |
| Goodwill | 3.90M | 3.90M | 3.90M | 3.90M | 3.90M | 3.90M | 0 | |||
| Total assets | 327.9M | 230.3M | 118.3M | 129.2M | 93.7M | 99.5M | 68.8M | 49.4M | 14.8M | 8.49M |
| Accounts payable | 3.68M | 4.69M | 1.40M | 2.20M | 1.07M | 3.73M | 3.50M | 3.24M | 4.42M | 2.41M |
| Current liabilities | 135.8M | 41.8M | 18.6M | 8.80M | 7.33M | 11.7M | 16.9M | 8.25M | 30.5M | 12.1M |
| Long-term debt | 132.9M | 97.4M | 43.4M | 19.9M | 10.4M | 10.3M | 10.3M | 11.6M | 5.56M | 5.22M |
| Total debt | 197.9M | 122.4M | 49.5M | 19.9M | 10.4M | 10.3M | 15.9M | 12.8M | 23.5M | 8.68M |
| Total liabilities | 283.2M | 150.9M | 71.0M | 38.8M | 28.5M | 28.4M | 33.9M | 30.7M | 48.5M | 26.7M |
| Shareholders' equity | 44.7M | 79.4M | 47.3M | 90.4M | 65.3M | 71.1M | 34.9M | 18.7M | -33.7M | -18.2M |
| Shares outstanding | 87.2M | 84.7M | 68.6M | 64.5M | 52.3M | 43.3M | 28.2M | 7.16M | 8.59M | 5.09M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -35.7M | -93.4M | -41.6M | -28.6M | -34.0M | -54.1M | -48.3M | -31.8M | -24.3M | -13.9M |
| Capital spending | -4.34M | -4.95M | -1.29M | -592.0K | -107.0K | -752.1K | -1.85M | -870.9K | -2.54M | -2.89M |
| Free cash flow | -40.0M | -98.4M | -42.9M | -29.2M | -34.1M | -54.9M | -50.1M | -32.7M | -26.8M | -16.8M |
| Cash from investing | -6.34M | -8.44M | -11.3M | -587.0K | -107.0K | 247.9K | -1.85M | -870.9K | -2.54M | -2.89M |
| Cash from financing | 59.7M | 194.7M | 43.2M | 65.0M | 26.3M | 63.4M | 66.4M | 68.8M | 28.8M | 6.11M |
| Share buybacks | 62.4M | 72.8M | 96.7K | 445.5K | ||||||
| Change in cash | 17.7M | 92.8M | -9.60M | 35.8M | -7.82M | 9.52M | 16.3M | 36.1M | 1.98M | -10.7M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 19, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 18, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 18, 2026 | Management or board change | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Oct 13, 2026 | Material contract | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 30, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 15, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 14, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 11, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 3, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 21, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 19, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 19, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 17, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 4, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 8, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 17, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 10, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 8, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 8, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 21, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 20, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 15, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 14, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 11, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | May 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 11, 2026 | Results | SEC |
| 144 · Notice of proposed sale | May 8, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 7, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 24, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 21, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 17, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 16, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 14, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 14, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 9, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 30, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 27, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 26, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 13, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 9, 2026 | Other filings | SEC |
| S-3ASR · Registration statement | Mar 5, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 5, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 5, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 5, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 5, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 9, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 13, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 9, 2026 | Current report | SEC |
| 4 · Change in ownership | Dec 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 18, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 7, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 5, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 3, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 3, 2025 | Results | SEC |
| 8-K · Current report | Oct 30, 2025 | Material contract | SEC |
| 4 · Change in ownership | Oct 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Sep 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 15, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 5, 2025 | Insider trade | SEC |
This page holds 200 of 710 filings. Open Filings
Cap table
Built by 6ix from Liquidia Corporation’s releases · as of Oct 28, 2026
- Common shares
- 90,106,442
- Fully diluted
- 90,106,442
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 90,106,442 | Oct 28, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 28, 2026 | 90,106,442 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Paul B. Manning Other companies: Candel Therapeutics, Inc. (Chair of the Board · Since at least Jul 26, 2021); Verrica Pharmaceuticals Inc. (Chairman · Since at least Jun 14, 2018); Taysha Gene Therapies, Inc. (Director · Sep 23, 2020 – Oct 31, 2022 · Past); Dova Pharmaceuticals Inc (Director · Jun 28, 2017 – Nov 12, 2019 · Past); AveXis Inc (Director · Feb 10, 2016 – Feb 10, 2016 · Past); Perrigo Company plc (EVP & General Manager, PBM · Jun 9, 2010 – Jun 9, 2010 · Past) | Board Member · Since at least Nov 18, 2020 |
| Roger Jeffs Other companies: Axsome Therapeutics, Inc. (DIRECTOR · Since at least Nov 19, 2015); Sio Gene Therapies Inc (Director · Feb 8, 2018 – Apr 15, 2019 · Past); Albireo Pharma Inc (Director · Sep 27, 2017 – Jun 24, 2021 · Past); Dova Pharmaceuticals Inc (Director · Jun 28, 2017 – Nov 12, 2019 · Past); Sangamo Therapeutics, Inc. (Director · Jun 26, 2017 – Sep 7, 2018 · Past); United Therapeutics Corporation (President & Co-CEO, Director · Jan 5, 2006 – Mar 15, 2016 · Past) | Chief Executive Officer · Since at least Nov 18, 2020 |
| Arthur Kirsch Other companies: Evommune, Inc. (Audit · Since at least Nov 5, 2025); Atea Pharmaceuticals, Inc. (Director · Since at least Feb 20, 2025); Kadmon Holdings Inc (Director · May 15, 2019 – Nov 9, 2021 · Past); Aralez Pharmaceuticals Inc (Director · May 12, 2016 – Dec 8, 2017 · Past) | Board Member · Since at least Mar 24, 2021 |
| Michael Kaseta Other companies: Heron Therapeutics, Inc. (Director · Since at least Nov 4, 2024); Alimera Sciences Inc (Director · Mar 24, 2023 – Sep 16, 2024 · Past); Aralez Pharmaceuticals Inc (Chief Financial Officer · Nov 30, 2017 – Mar 15, 2018 · Past) | CFO and COO · Since at least Nov 30, 2020 |
| Stephen Bloch Other companies: Marinus Pharmaceuticals Inc (Director · Jul 31, 2014 – Sep 24, 2015 · Past); Amicus Therapeutics Inc (Director · May 30, 2007 – Feb 11, 2009 · Past) | Chairman · Since at least Mar 24, 2021 |
| Joanna Horobin Other companies: Kymera Therapeutics, Inc. (Director · Jun 7, 2024 – Jun 7, 2024 · Past) | Director · Since at least Jun 20, 2024 |
| Damian deGoa | Director · Since at least Jun 17, 2025 |
| Dana Boyle | Chief Accounting Officer · Since at least Jul 1, 2025 |
| David Johnson | Director · Since at least May 19, 2026 |
| Harold Alterson | See Remarks · Since at least Nov 16, 2026 |
All 22 people
| Person | Seat |
|---|---|
| Jason Adair | Chief Business Officer · Since at least Jul 21, 2021 |
| Katherine Rielly-Gauvin | Director · Since at least Jun 16, 2026 |
| Katie Rielly-Gauvin | Board Member · Since at least Aug 21, 2026 |
| Patrick Wallace | Director, Corporate Communications · Since at least Jan 27, 2026 |
| Rajeev Saggar | Chief Medical Officer · Since at least Jul 18, 2022 |
| Raman Singh | Board Member · Since at least Mar 24, 2021 |
| Robert A Lippe | Chief Operations Officer · Nov 30, 2023 – Nov 30, 2023 · Past |
| Russell Schundler | See Remarks · Since at least Mar 29, 2021 |
| Sanjeev Khindri | Chief Development Officer · Since at least Jan 1, 2026 |
| Sarah Krepp | Chief Human Resource Officer · Since at least Jul 1, 2025 |
| Scott Moomaw | Chief Commercial Officer · Since at least Nov 18, 2020 |
| Tushar Shah | CMO and Head of R&D · Jan 19, 2021 – Jan 16, 2022 · Past |
Log in to ask 6ix AI your own questions about Liquidia Corporation.